The global biosimilar monoclonal antibodies market is projected to reach a value of over US$ 32,000.0 Mn in 2026 at a CAGR of 35.7% over the forecast period. The first five-year cumulative revenue (2017–2021) is projected to be US$ 20,543.2 Mn, which is expected to increase rather significantly over the latter part of the five-year forecast period.
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Global Biosimilar Monoclonal Antibodies Market: Market Dynamics
Major factor driving growth of the global biosimilar monoclonal antibodies market is patent expiry on essential biological drugs. These patent expiries allow manufacturers to produce biosimilar drugs in bulk quantities and offer it to the general public at much cost-effective rates. Also, a number of pipeline products and increasing cases of chronic and autoimmune diseases are other factors expected to fuel growth of the global biosimilar monoclonal antibodies market over the forecast period. Moreover, recent approvals by prominent regulatory bodies in developed economies for biosimilar monoclonal antibodies is another factor expected to boost adoption of biosimilar MAB and in turn propel growth of the global market to a significant extent.
However, unfavorable regulatory scenarios in multiple regions coupled with lack of proper reimbursement policies for biosimilar products are major factors restraining growth of the global biosimilar monoclonal antibodies market. Additionally, possible side effects of monoclonal antibodies (MAB) products is another factor anticipated to hamper growth of the global monoclonal antibodies market over the forecast period.
Get Free Sample Copy Of This Research @ https://marketresearch.biz/report/biosimilar-monoclonal-antibodies-market/request-sample/
Global Biosimilar Monoclonal Antibodies Market: Segmental Snapshot
The global biosimilar monoclonal antibodies market report has been segmented on the basis of drug class, application, and region. The drug class segment includes Rituximab, Infliximab, Abciximab, Trastuzumab, Adalimumab, and Bevacizumab. Application segment includes oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others. The regions covered in the analysis are The Americas, Europe, Asia Pacific, and Rest of the World.
By drug class:
On the basis of drug class segmentation, Adalimumab segment is estimated to account for major revenue share in the global market and is projected to register highest CAGR of around 37.0% over the forecast period. This can be attributed to increasing incidence of chronic psoriasis and Crohn's disease for which Adalimumab is used as a primary medication. It is commercially available under the trade name Humira. Also, the Adalimumab segment in the global biosimilar monoclonal antibodies market is projected to maintain its dominant revenue contribution in the global market over the forecast period.
By application:
Among the application segments, the oncology segment accounted for highest revenue share in the global biosimilar monoclonal antibodies market, and is expected to register highest CAGR of around 38.0% during the forecast period 2017 & 2026. It is further projected to maintain its dominant revenue contribution over the forecast period, owing to increasing use of biosimilar monoclonal antibodies (MAB) in the field of oncology in developed and developing economies.
By region:
The market in the Americas dominated the global biosimilar monoclonal antibodies market in revenue terms, and is estimated to account for largest market revenue contribution of US$ 618.4 million in 2017 as compared to that of markets in other regions. It is further expected to maintain its dominant revenue contribution in the global biosimilar monoclonal antibodies market over the forecast period. This can be attributed to presence of advanced healthcare facilities, growing demand for biosimilar products, and increasing adoption of biosimilar monoclonal antibodies in the region.
Moreover, high rate of approvals for biosimilar monoclonal antibodies (MAB) by the Food and Drug Administration (FDA) in recent times is also a major factor boosting growth of the Americas market. Also, high number of pipeline drugs in the Americas market is a major factor for growth of the Americas biosimilar monoclonal antibodies market.
For Any Inquiry Or Purchasing The Report @ https://marketresearch.biz/purchase-report/?report_id=313
Global Biosimilar Monoclonal Antibodies Market: Competitive Analysis
The research report on the global biosimilar monoclonal antibodies market includes major company profiles such as Pfizer Inc., Novartis AG, Reliance Life Sciences, Biocon, Intas Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, BioXpress Therapeutics, SA., Coherus BioSciences, Inc., Genor BioPharma Co. Ltd., Allergan PLC, Celltrion Healthcare Co. Ltd., and Dr. Reddy's Laboratories Ltd.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
